Frost & Sullivan releases theGlobal Gene Therapy Industry Development Blue Book for 2026Frost & Sullivan Frost & Sullivan China LeadLeo Research Institute LeadLeo YUAN CAPITAL SULLIVAN TELE-TREND CLOUD TECHNOLOGY TradeGo MagnaTEC Automotive & Mobility Environmental Protection & Energy Saving Technology Logistics & Supply Chain MATERNAL AND INFANT Education & Training Real Estate & Property Catering & New Retailing Advanced Materials Healthcare & Life Sciences Semiconductor & Chip COMMERCIAL AVIATION Technology, Media and Telecom LANDSCAPING Big Data & AI Infrastructure Construction & Utilities Culture & Entertainment AGRICULTURE, FORESTRY ANIMAL HUSBANDRY AND FISHERY Food & Beverage Fintech SHIPPING AND PORTS Dual Carbon & New Energy Mining & Metals Public Sector Cross-Border E-commerce Trade Building Technology, Construction & Decoration Beauty & Fashion Smart Homes Digital Infrastructure Enterprise Services Consumer Electronics
Frost & Sullivan releases the " Global Gene Therapy Industry Development Blue Book "
Frost & Sullivan released the '2026 Global Gene Therapy Industry Development Blue Book', which systematically reviews the current status and future trends of the global gene therapy industry, driven by technological breakthroughs, improved regulations, capital investment, and commercial implementation. The Blue Book analyzes aspects such as the industry's development history, core classifications, policy and capital dynamics, supply chain上下游, viral vector production bottlenecks, clinical progress in key indications, reimbursement pathways, and market landscape. It focuses on identifying key challenges and opportunities in vector technologies, scale-up manufacturing, clinical translation, commercial reimbursement, and regulatory frameworks. By connecting industry chain companies, investment institutions, and regulatory authorities, the Blue Book provides forward-looking market insights and strategic references for corporate technology planning, product development, industrialization decisions, international cooperation, and the refinement of industry standards
Frost & Sullivan's release of the 2026 Global Gene Therapy Industry Development Blue Book aims to systematically review the current state and future trends of the global gene therapy industry, driven by concurrent advances in technological breakthroughs, regulatory improvements, capital investment, and commercial rollout. The Blue Book will analyze the industry's development history, core classifications, policy and capital dynamics, upstream and downstream supply chains, viral vector production bottlenecks, clinical progress in key indications, reimbursement pathways, and competitive landscape, with a particular focus on identifying critical challenges and opportunities in vector technologies, scale-up manufacturing, clinical translation, commercial reimbursement, and regulatory frameworks. By connecting industry chain players, investment institutions, and regulatory bodies, the Blue Book seeks to provide forward-looking market insights and strategic references for corporate technology planning, product development, industrialization decisions, international collaboration, and the refinement of industry standards
Click on the following link to view the summary version of the report:
If you have further research needs regarding the 'Global Gene Therapy Industry Development Blue Book', please contact us:
Mr. Mao Mao from Frost & Sullivan
E-mail: fred.mao@frostchina.com
